Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome.

Cattafi A, Santarpia M, Micalizzi MF, Sofia C, Condorelli E, Dottore A, Altavilla G, Blandino A, Ascenti G, Marino MA.

BJR Case Rep. 2019 Nov 15;5(4):20190064. doi: 10.1259/bjrcr.20190064. eCollection 2019 Dec.

2.

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.

Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R.

Pharmacogenomics J. 2019 Dec;19(6):556-563. doi: 10.1038/s41397-019-0077-1. Epub 2019 Feb 6.

3.

Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer.

Lazzari C, Gregorc V, Bulotta A, Dottore A, Altavilla G, Santarpia M.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S329-S333. doi: 10.21037/tlcr.2018.12.02. No abstract available.

4.

MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer.

Callegari E, Domenicali M, Shankaraiah RC, D'Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin BK, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini EM, Gramantieri L, Sabbioni S, Negrini M.

Mol Ther Nucleic Acids. 2019 Mar 1;14:239-250. doi: 10.1016/j.omtn.2018.11.018. Epub 2018 Dec 6.

5.

Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.

Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F.

Tumour Biol. 2018 Nov;40(11):1010428318815047. doi: 10.1177/1010428318815047.

PMID:
30486741
6.

Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.

De Laurentiis M, Bonfadini C, Lorusso V, Cilenti G, Di Rella F, Altavilla G, Otero M, Ardizzoia A, Marchetti P, Peverelli G, Amoroso D, Vecchio S, Fiorio E, Orecchia S.

Support Care Cancer. 2018 Dec;26(12):4021-4029. doi: 10.1007/s00520-018-4259-1. Epub 2018 Jun 25.

PMID:
29943152
7.

miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.

Callegari E, D'Abundo L, Guerriero P, Simioni C, Elamin BK, Russo M, Cani A, Bassi C, Zagatti B, Giacomelli L, Blandamura S, Moshiri F, Ultimo S, Frassoldati A, Altavilla G, Gramantieri L, Neri LM, Sabbioni S, Negrini M.

Mol Ther Nucleic Acids. 2018 Jun 1;11:485-493. doi: 10.1016/j.omtn.2018.04.002. Epub 2018 Apr 12.

8.

Liquid biopsy for lung cancer early detection.

Santarpia M, Liguori A, D'Aveni A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, Lazzari C, Altavilla G, Rosell R.

J Thorac Dis. 2018 Apr;10(Suppl 7):S882-S897. doi: 10.21037/jtd.2018.03.81. Review.

9.

Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy.

Lucchesi S, Marcianò I, Panagia P, Intelisano R, Randazzo MP, Sgroi C, Altavilla G, Santarpia M, Adamo V, Franchina T, Ferraù F, Reitano P, Trifirò G.

Clin Drug Investig. 2018 Mar;38(3):279-285. doi: 10.1007/s40261-017-0613-1.

10.

Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.

Lucchesi S, Marcianò I, Panagia P, Intelisano R, Randazzo MP, Sgroi C, Altavilla G, Santarpia M, Adamo V, Franchina T, Ferraù F, Reitano P, Trifirò G.

Clin Drug Investig. 2018 Mar;38(3):269-278. doi: 10.1007/s40261-017-0591-3. Erratum in: Clin Drug Investig. 2017 Dec 30;:.

11.

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R.

Lung Cancer (Auckl). 2017 Aug 18;8:109-125. doi: 10.2147/LCTT.S119644. eCollection 2017. Review.

12.

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G.

Drug Des Devel Ther. 2017 Jul 5;11:2047-2063. doi: 10.2147/DDDT.S113500. eCollection 2017. Review.

13.

Nail toxicities induced by liposomal doxorubicin: a retrospective case series.

Vaccaro M, Santarpia M, Borgia F, Giuffrida R, Altavilla G, Piraccini BM, Cannavò SP.

Eur J Dermatol. 2017 Aug 1;27(4):434-435. doi: 10.1684/ejd.2017.3047. No abstract available.

PMID:
28508752
14.

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

Lazzari C, Karachaliou N, Gregorc V, Bulotta A, Gonzalez-Cao M, Verlicchi A, Altavilla G, Rosell R, Santarpia M.

Expert Rev Respir Med. 2017 Jun;11(6):469-479. doi: 10.1080/17476348.2017.1326822. Epub 2017 May 15. Review.

PMID:
28467720
15.

Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.

Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote A, Altavilla G, Rosell R.

Expert Opin Investig Drugs. 2017 Jun;26(6):713-722. doi: 10.1080/13543784.2017.1324572. Epub 2017 May 18. Review.

PMID:
28463570
16.

HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.

Cafaro A, Piccaro G, Altavilla G, Gigantino V, Matarese G, Olivieri E, Ferrantelli F, Ensoli B, Palma C.

BMC Infect Dis. 2016 Aug 22;16(1):442. doi: 10.1186/s12879-016-1724-7.

17.

Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications.

Di Paolo A, Del Re M, Petrini I, Altavilla G, Danesi R.

Epigenomics. 2016 Aug;8(8):1151-67. doi: 10.2217/epi.16.10. Epub 2016 Aug 1. Review.

PMID:
27479016
18.

Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?

Mondello P, Mian M, Pitini V, Cuzzocrea S, Sindoni A, Galletti M, Mandolfino M, Santoro D, Mondello S, Aloisi C, Altavilla G, Benvenga S.

Curr Oncol. 2016 Jun;23(3):e165-70. doi: 10.3747/co.23.3026. Epub 2016 Jun 9.

19.

Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.

Vaccaro M, Santarpia M, Calapai G, Mannucci C, Borgia F, Altavilla G, Cannavò SP.

Br J Dermatol. 2017 Feb;176(2):507-509. doi: 10.1111/bjd.14806. Epub 2016 Dec 27. No abstract available.

PMID:
27291307
20.

Recent developments in the use of immunotherapy in non-small cell lung cancer.

Santarpia M, Giovannetti E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G, Rosell R.

Expert Rev Respir Med. 2016 Jul;10(7):781-98. doi: 10.1080/17476348.2016.1182866. Epub 2016 May 13. Review.

PMID:
27148808
21.

Feasibility of cell-free circulating tumor DNA testing for lung cancer.

Santarpia M, Karachaliou N, González-Cao M, Altavilla G, Giovannetti E, Rosell R.

Biomark Med. 2016;10(4):417-30. doi: 10.2217/bmm.16.6. Epub 2016 Mar 14. Review.

PMID:
26974841
22.

Targeted drugs in small-cell lung cancer.

Santarpia M, Daffinà MG, Karachaliou N, González-Cao M, Lazzari C, Altavilla G, Rosell R.

Transl Lung Cancer Res. 2016 Feb;5(1):51-70. doi: 10.3978/j.issn.2218-6751.2016.01.12. Review.

23.

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.

Santarpia M, González-Cao M, Viteri S, Karachaliou N, Altavilla G, Rosell R.

Transl Lung Cancer Res. 2015 Dec;4(6):728-42. doi: 10.3978/j.issn.2218-6751.2015.12.04. Review.

24.

Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.

Vaccaro M, Guarneri F, Borgia F, Pollicino A, Altavilla G, Cannavò SP.

J Dermatolog Treat. 2016;27(2):148-52. doi: 10.3109/09546634.2015.1086478. Epub 2015 Sep 24.

PMID:
26313697
25.

Efficacy of clindamycin phosphate and benzoyl peroxide gel (DUAC(®) ) in the treatment of EGFR inhibitors-associated acneiform eruption.

Vaccaro M, Guarneri F, Borgia F, Pollicino A, Altavilla G, Cannavò SP.

J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1436-8. doi: 10.1111/jdv.13278. Epub 2015 Aug 20. No abstract available.

PMID:
26290481
26.

Thyroid function, autoimmunity and nodules in hematological malignancies.

Mondello P, Sindoni A, Pitini V, Scisca C, Altavilla G, Benvenga S.

Arch Endocrinol Metab. 2015 Jun;59(3):236-44. doi: 10.1590/2359-3997000000044.

27.

Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.

Santarpia M, Altavilla G, Pitini V, Rosell R.

Future Oncol. 2015;11(8):1259-74. doi: 10.2217/fon.14.320. Review.

PMID:
25832881
28.

Should the use of surveillance imaging in diffuse large B-cell lymphoma be discontinued?

Pitini V, Arrigo C, Di Mirto C, Garufi L, Mondello P, d'Aquino A, Altavilla G.

J Clin Oncol. 2015 May 10;33(14):1623. doi: 10.1200/JCO.2014.60.0627. Epub 2015 Mar 23. No abstract available.

PMID:
25800759
29.

Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.

Santarpia M, Altavilla G, Rosell R.

Expert Rev Respir Med. 2015 Jun;9(3):255-68. doi: 10.1586/17476348.2015.1009040. Epub 2015 Feb 5.

PMID:
25652176
30.

Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature.

Mondello P, Pitini V, Arrigo C, Mondello S, Mian M, Altavilla G.

Springerplus. 2014 Mar 5;3:123. doi: 10.1186/2193-1801-3-123. eCollection 2014.

31.

Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation.

Lacquaniti A, Altavilla G, Picone A, Donato V, Chirico V, Mondello P, Aloisi C, Marabello G, Loddo S, Buemi A, Lorenzano G, Buemi M.

Clin Exp Med. 2015 Feb;15(1):97-105. doi: 10.1007/s10238-014-0272-y. Epub 2014 Jan 28.

PMID:
24469934
32.

Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions.

Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, Doetsch PW.

PLoS One. 2013 Nov 19;8(11):e81162. doi: 10.1371/journal.pone.0081162. eCollection 2013.

33.

Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.

Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, Kirby BJ, Giannakakou P.

Lab Chip. 2014 Jan 7;14(1):147-56. doi: 10.1039/c3lc51039e. Epub 2013 Nov 7.

34.

Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.

Callegari E, Elamin BK, D'Abundo L, Falzoni S, Donvito G, Moshiri F, Milazzo M, Altavilla G, Giacomelli L, Fornari F, Hemminki A, Di Virgilio F, Gramantieri L, Negrini M, Sabbioni S.

PLoS One. 2013 Sep 12;8(9):e73964. doi: 10.1371/journal.pone.0073964. eCollection 2013.

35.

Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.

Pitini V, Arrigo C, Di Mirto C, Mondello P, Altavilla G.

Lung Cancer. 2013 Oct;82(1):171-2. doi: 10.1016/j.lungcan.2013.07.004. Epub 2013 Aug 9.

PMID:
23932362
36.

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).

Binda D, Vanhoutte EK, Cavaletti G, Cornblath DR, Postma TJ, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi MG, Faber CG, Merkies IS; CI-PeriNomS study group, Galimberti S, Lanzani F, Mattavelli L, Piatti ML, Bidoli P, Cazzaniga M, Cortinovis D, Lucchetta M, Campagnolo M, Bakkers M, Brouwer B, Boogerd W, Grant R, Reni L, Piras B, Pessino A, Padua L, Granata G, Leandri M, Ghignotti I, Plasmati R, Pastorelli F, Heimans JJ, Eurelings M, Meijer RJ, Grisold W, Lindeck Pozza E, Mazzeo A, Toscano A, Russo M, Tomasello C, Altavilla G, Penas Prado M, Dominguez Gonzalez C, Dorsey SG.

Eur J Cancer. 2013 Sep;49(13):2910-8. doi: 10.1016/j.ejca.2013.04.004. Epub 2013 May 10.

PMID:
23668917
37.

Questionable validity of cardiac risk score on the basis of the NSABP B-31 model.

Pitini V, Arrigo C, Mondello P, Altavilla G.

J Clin Oncol. 2013 Jun 10;31(17):2224. doi: 10.1200/JCO.2012.47.2696. Epub 2013 May 6. No abstract available.

PMID:
23650420
38.

Circulating mitotic figures in a patient with dual infection by Epstein-Barr virus and cytomegalovirus.

Pitini V, Arrigo C, Mondello P, Sturniolo G, Altavilla G.

Eur J Haematol. 2015 Jan;94(1):89. doi: 10.1111/ejh.12132. Epub 2013 Jun 28. No abstract available.

PMID:
23646993
39.

Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy.

Saitta C, Musolino C, Marabello G, Martino D, Leonardi MS, Pollicino T, Altavilla G, Raimondo G.

Dig Liver Dis. 2013 Aug;45(8):683-6. doi: 10.1016/j.dld.2013.01.022. Epub 2013 Mar 11.

PMID:
23490344
40.

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.

Santarpia M, De Pas TM, Altavilla G, Spaggiari L, Rosell R.

Future Oncol. 2013 Mar;9(3):327-45. doi: 10.2217/fon.13.6.

PMID:
23469969
41.

Increased excitability in tat-transgenic mice: role of tat in HIV-related neurological disorders.

Zucchini S, Pittaluga A, Brocca-Cofano E, Summa M, Fabris M, De Michele R, Bonaccorsi A, Busatto G, Barbanti-Brodano G, Altavilla G, Verlengia G, Cifelli P, Corallini A, Caputo A, Simonato M.

Neurobiol Dis. 2013 Jul;55:110-9. doi: 10.1016/j.nbd.2013.02.004. Epub 2013 Feb 27.

PMID:
23454193
42.

Fatal Hepatocellular Carcinoma in a Patient with Occult Hepatitis B Virus Infection following the Administration of R-CHOP for Diffuse Large B-Cell Lymphoma.

Pitini V, Rizzo M, Arrigo C, Mondello P, Altavilla G.

Case Rep Hematol. 2012;2012:803298. doi: 10.1155/2012/803298. Epub 2012 Dec 26.

43.

Malignant perivascular epithelioid cell tumor of the esophagus.

Fassan M, Cassaro M, Vecchiato M, Clemente R, Pennelli G, Merigliano S, Altavilla G.

Case Rep Pathol. 2012;2012:438505. doi: 10.1155/2012/438505. Epub 2012 Aug 22.

44.

Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.

Gori S, Clavarezza M, Siena S, Foglietta J, Tarenzi E, Giordano M, Molino A, Graiff C, Fusco V, Alabiso O, Baldini E, Gamucci T, Altavilla G, Dondi D, Venturini M.

BMC Cancer. 2012 Apr 30;12:158. doi: 10.1186/1471-2407-12-158.

45.

Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.

Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, Giacomelli L, D'Abundo L, Ferracin M, Bassi C, Zagatti B, Corrà F, Miotto E, Lupini L, Bolondi L, Gramantieri L, Croce CM, Sabbioni S, Negrini M.

Hepatology. 2012 Sep;56(3):1025-33. doi: 10.1002/hep.25747. Epub 2012 Jul 13.

PMID:
22473819
46.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
47.

A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report.

Pasello G, Altavilla G, Bonanno L, Rea F, Favaretto AG.

J Thorac Dis. 2010 Dec;2(4):254. doi: 10.3978/j.issn.2072-1439.2010.02.04.2.

48.

Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily.

Rizzo M, Sindoni A, Talamo Rossi R, Bonaffini O, Panetta S, Scisca C, Altavilla G, Denaro L, Rosanò A, Saraceno G, Trimarchi F, Benvenga S.

Hormones (Athens). 2013 Jan-Mar;12(1):46-57.

49.

Risk of second malignant neoplasm among patients with lymphoma.

Pitini V, Arrigo C, Sauta MG, Altavilla G.

J Clin Oncol. 2011 Oct 1;29(28):3834; author reply 3834-5. doi: 10.1200/JCO.2011.37.2144. Epub 2011 Aug 29. No abstract available.

PMID:
21876085
50.

Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.

Pitini V, Cascio A, Arrigo C, Altavilla G.

Br J Haematol. 2012 Jan;156(1):1. doi: 10.1111/j.1365-2141.2011.08802.x. Epub 2011 Jul 25. No abstract available.

PMID:
21790529

Supplemental Content

Loading ...
Support Center